Follow the 넥스트바이오메디컬 stock price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares are quoted on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 넥스트바이오메디컬 has published 18 public disclosures. Market capitalisation: €297.8bn. The latest transaction was filed on 25 June 2026 (Purchase). Among the most active insiders: 이은혜. Every trade is openly available.
18
Insider Decl.
n/a
Thresholds
n/a
14 ops.
Buy Volume
n/a
2 ops.
Sell Volume
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,028 of 29,063 companies
34.0
score / 100
Value
33
Quality
35
FCF yld-0.7%
Earn yld-0.1%
EV/EBITDA·
ROE-0.1%
Gross mgn70%
Net mgn-1.9%
Debt/EBITDA13.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.